What is BIAF's health score?

bioAffinity Technologies, Inc. (BIAF) has a TradeApes health score of 30 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is BIAF's estimated fair value?

Based on our 5-year discounted cash flow model, bioAffinity Technologies, Inc.'s estimated fair value is $2.16 per share, representing a 14.7% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is BIAF undervalued or overvalued?

Our model currently rates BIAF as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for BIAF... Refresh in a moment for the full analysis.

bioAffinity Technologies, Inc. (BIAF)

Industrials Undervalued low weak

$1.88

Updated: 2026-06-04

TradeApes Score

Financial Strength

30 Weak

Operating Trend

10 Stressed

Relative Value

40 Weak

Capital Allocation

40 Weak

Risk

35 Weak

Est. Fair Value $2.16

DCF Upside +14.7%

Sector Rank #1397 of 3776

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.